Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors

How macrophage–drug conjugates are transforming solid-tumor cell therapy

European biotech company Cellis has developed breakthrough platform technology to overcome the limitations of current solid-tumor treatments and provide life-changing therapies for cancer patients, advancing the field of precision oncology.

Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors

CHENGDU, China, March 25, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-001) from…

China’s NMPA Approves IND for SKB107 for Solid Tumor Bone Metastases

The investigational new drug application for the RDC SKB107 for the management of solid tumor bone metastases has been approved in China.

Significant progress in R&D and commercialization, gross profit increased by 68% Financial Highlights Revenue was approximately RMB1,933.0 million, a year-on-year increase of 25.5%. Gross profit was approximately RMB1,273.7 million, a year-on-year increase of 67.8%. Research and development expenses were approximately RMB1,206.1 million, a year-on-year increase of 17.0%. The annual loss was approximately RMB 266.8 million. Adjusted loss for the …